Satralizumab

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 197 publications

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: JAMA neurology
Published: July 13, 2026

Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases.

Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases.

Journal: Frontiers in neurology
Published: May 21, 2026

Satralizumab could reduce relapse risk in people with MOGAD.

Satralizumab could reduce relapse risk in people with MOGAD.

Journal: Nature reviews. Neurology
Published: May 06, 2026

How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder?

How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder?

Journal: Expert review of neurotherapeutics
Published: May 02, 2026

AQP4-IgG Dynamics and Exploratory Assessment of SERA-3 in Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab.

AQP4-IgG Dynamics and Exploratory Assessment of SERA-3 in Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab.

Journal: Neurology and therapy
Published: May 01, 2026

AQP4-IgG-positive myelitis occurring in a patient with small cell lung cancer: a case report.

AQP4-IgG-positive myelitis occurring in a patient with small cell lung cancer: a case report.

Journal: Frontiers in oncology
Published: April 29, 2026

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials.

Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials.

Journal: Ophthalmology
Published: April 29, 2026

Bridging to low-dose corticosteroids after satralizumab discontinuation in unplanned pregnancy: Two cases of AQP4-positive NMOSD.

Bridging to low-dose corticosteroids after satralizumab discontinuation in unplanned pregnancy: Two cases of AQP4-positive NMOSD.

Journal: Multiple sclerosis and related disorders
Published: April 11, 2026

Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease.

Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease.

Journal: Neurologic clinics
Published: April 01, 2026

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.

Journal: Neurological research and practice
Published: March 24, 2026

Intitiation of satralizumab during pregnancy for successful childbirth in neuromyelitis optica spectrum disorder: A case report and literature review.

Intitiation of satralizumab during pregnancy for successful childbirth in neuromyelitis optica spectrum disorder: A case report and literature review.

Journal: Journal of neuroimmunology
Published: March 21, 2026

Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report.

Satralizumab in the management of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder during pregnancy: a case report.

Journal: Frontiers in immunology
Published: March 18, 2026
Showing 1-12 of 197

Last Updated: 09/26/2026